Standard Duration After Stent Placement
Guidelines recommend dual antiplatelet therapy (DAPT) with Brilinta (ticagrelor) plus aspirin for at least 6 months after placement of a drug-eluting stent (DES) in patients with acute coronary syndrome (ACS). For stable ischemic heart disease, it's typically 6 months. The PLATO trial, which supported Brilinta's approval, showed benefits up to 12 months in ACS patients.[1][2]
Factors That Extend or Shorten Duration
High-risk patients—those with prior myocardial infarction, diabetes, complex stents, or high bleeding risk—may need 12 months or longer, up to 30 months per some trials like PEGASUS-TIMI 54. Shorter durations (1-3 months) apply if bleeding risk outweighs thrombosis risk, per 2023 ACC/AHA guidelines.[3][4]
| Patient Profile | Recommended Minimum DAPT Duration |
|-----------------|-----------------------------------|
| ACS with DES | 12 months |
| Stable CAD with DES | 6 months |
| High thrombotic risk | >12 months |
| High bleeding risk | 1-3 months (then monotherapy) |
What Happens If You Stop Early or Late
Stopping Brilinta prematurely increases stent thrombosis risk by 2-5 fold within 30 days, based on observational data. Prolonged use beyond 12 months raises bleeding risk without proportional benefit in low-risk cases. Transition to aspirin monotherapy or low-dose Brilinta alone is common after initial DAPT.[5]
Alternatives to Brilinta for DAPT
Brilinta is often paired with aspirin but can be swapped for clopidogrel (Plavix) if intolerance occurs, though Brilinta shows superior efficacy in ACS per PLATO. Newer options like prasugrel (Effient) suit certain profiles; cangrelor is IV for peri-procedural use.[6]
When to Talk to Your Doctor
Duration is personalized based on your ejection fraction, kidney function, bleeding history, and procedure details—guidelines stress shared decision-making. Never adjust without consulting your cardiologist, as self-stopping can be fatal.[7]
[1]: FDA Brilinta Label
[2]: PLATO Trial (NEJM 2009)
[3]: 2023 ACC/AHA ACS Guidelines
[4]: PEGASUS-TIMI 54 (NEJM 2015)
[5]: THEMIS Trial (NEJM 2019)
[6]: DrugPatentWatch.com - Ticagrelor Patents
[7]: AHA Stent Guidelines